Johnson Investment Counsel Inc. Has $130.71 Million Stock Position in Abbott Laboratories $ABT

Johnson Investment Counsel Inc. cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 975,877 shares of the healthcare product maker’s stock after selling 12,764 shares during the period. Abbott Laboratories comprises approximately 1.1% of Johnson Investment Counsel Inc.’s investment portfolio, making the stock its 22nd biggest position. Johnson Investment Counsel Inc. owned approximately 0.06% of Abbott Laboratories worth $130,709,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. IMG Wealth Management Inc. raised its holdings in Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares during the last quarter. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories during the third quarter valued at $29,000. Guerra Advisors Inc acquired a new position in shares of Abbott Laboratories during the third quarter worth $31,000. Anfield Capital Management LLC grew its stake in shares of Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC acquired a new stake in Abbott Laboratories in the second quarter valued at $32,000. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the acquisition, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. The trade was a 0.15% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. BTIG Research decreased their price target on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Piper Sandler decreased their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research report on Friday, January 23rd. Mizuho boosted their price target on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 14th. Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Finally, Raymond James Financial dropped their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Stock Up 0.3%

Shares of NYSE ABT opened at $111.11 on Tuesday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The firm has a market cap of $193.21 billion, a PE ratio of 29.87, a P/E/G ratio of 1.76 and a beta of 0.75. The company’s fifty day simple moving average is $120.52 and its 200 day simple moving average is $126.80. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business’s revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be issued a $0.63 dividend. The ex-dividend date is Thursday, January 15th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.